Daniel Lee Flynn - Jan 18, 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role: Chief Scientific Officer
Signature: /s/ Thomas P. Kelly, Attorney-in-Fact
Stock symbol: DCPH
Transactions as of: Jan 18, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/20/2022, 04:00 PM
Previous filing: Dec 17, 2021
Next filing: Feb 18, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Award	$0	+20.5K	+71.35%	$0.00	49.2K	Jan 18, 2022	Direct	F1
holding	DCPH	Common Stock						230K	Jan 18, 2022	By Daniel L. Flynn Revocable Trust
holding	DCPH	Common Stock						91K	Jan 18, 2022	By Daniel L. Flynn Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DCPH	Stock Option (Right to Buy)	Award	$0	+82K		$0.00	82K	Jan 18, 2022	Common Stock	82K	$8.27	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person was awarded 20,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs shall vest in three (3) equal annual installments on each of January 15, 2023, January 15, 2024 and January 15, 2025.
F2	This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022.